Nagehan Emiralioglu
Overview
Explore the profile of Nagehan Emiralioglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Emiralioglu N, Kiper N
Eur J Clin Nutr
. 2024 Aug;
78(12):1023-1024.
PMID: 39107487
Growth failure and inadequate weight gain are common problems in childhood interstitial lung diseases (chILD) and these children usually need high calories. It is important to manage both pulmonary functions...
12.
Nayir Buyuksahin H, Yalcin E, Gokirmak I, Ertugrul G, Dayangac Erden D, Sennaroglu G, et al.
Pediatr Pulmonol
. 2024 Jul;
59(12):3298-3305.
PMID: 39073400
Objectives: To evaluate otorhinolaryngologic findings and the relationship between aminoglycoside (AG) exposure and hearing loss in paediatric patients with cystic fibrosis (cwCF). We also aimed to investigate the genetic predisposition...
13.
Ozsezen B, Yalcin E, Emiralioglu N, Konsuk Unlu H, Tural D, Caka C, et al.
Turk J Pediatr
. 2024 Jul;
66(3):297-308.
PMID: 39024602
Background: The lung clearance index (LCI) is a sensitive lung function index that is used to detect early lung disease changes in children with cystic fibrosis (CF). This study aimed...
14.
Kilic K, Vardar-Yagli N, Nayir-Buyuksahin H, Guzelkas I, Dogru D, Saglam M, et al.
Heart Lung
. 2024 Jul;
68:145-153.
PMID: 38981171
Background: Patients with cystic fibrosis (CF) experience increased oxidative stress. Tele-exercise can be a new method to improve exercise in CF. Objective: This study aimed to investigate the effect of...
15.
Emiralioglu N, Cakir B, Sertcelik A, Yalcin E, Kiper N, Sen V, et al.
Pediatr Pulmonol
. 2024 Jul;
59(11):2956-2966.
PMID: 38980199
Background: The decline in pulmonary function is a predictor of disease progression in patients with cystic fibrosis (CF). This study aimed to determine the decline rate of percent predicted forced...
16.
Raidt J, Riepenhausen S, Pennekamp P, Olbrich H, Amirav I, Athanazio R, et al.
Eur Respir J
. 2024 Jun;
64(2).
PMID: 38871375
Background: Primary ciliary dyskinesia (PCD) represents a group of rare hereditary disorders characterised by deficient ciliary airway clearance that can be associated with laterality defects. We aimed to describe the...
17.
Griese M, Schwerk N, Carlens J, Wetzke M, Emiralioglu N, Kiper N, et al.
Pediatr Pulmonol
. 2024 Jun;
59(10):2572-2579.
PMID: 38838063
Introduction: Childhood interstitial lung disease (chILD) is a heterogeneous group of mostly chronic respiratory disorders. Assessment of health-related quality of life (HrQoL) in chILD has become increasingly important in clinical...
18.
Nayir Buyuksahin H, Emiralioglu N, Yalcin E, Sen V, Selimoglu Sen H, Arslan H, et al.
Pediatr Pulmonol
. 2024 May;
59(10):2499-2506.
PMID: 38771207
Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all...
19.
Yavuz B, Yalcin E, Nayir Buyuksahin H, Sunman B, Guzelkas I, Alboga D, et al.
J Cyst Fibros
. 2024 May;
23(5):947-949.
PMID: 38762388
Novel drug therapy targeting the defective cystic fibrosis transmembrane conductance regulator protein has the potential to significantly enhance the quality of life for numerous patients with cystic fibrosis. However, in...
20.
Tural D, Emiralioglu N, Akin S, Alboga D, Ozsezen B, Nayir Buyuksahin H, et al.
Eur J Pediatr
. 2024 May;
183(8):3633-3634.
PMID: 38761224
No abstract available.